Cytokinetics

Join us for our CLIMB Symposium on May 29 in San Francisco! CLIMB brings together the scientific community to share innovative research in the field of muscle biology aimed at driving advancements. Register today: ClimbSymposium.com. #CLIMB26

We are thrilled to be on the ground at #ACC26 this weekend, and the energy is incredible. But the real excitement? Sharing that our first approved medicine is now available for patients. Please see full Prescribing Information, including Boxed WARNING: bit.ly/4dAIq2f

We’re excited to be attending #ACC26 in New Orleans, March 28 – 30. Visit us at booth #2237 to learn more about our research & science. We’ll also be presenting new data from our clinical research programs and hosting an industry product theater. #HCM #CardioTwitter

@Christo41039478 Our MYQORZO & You Patient Support Program may be able to help eligible patients when insurance coverage is an issue. For more information, connect with a MYQORZO Navigator at 833-MYQORZO (833-697-6796) available Monday through Friday 8 AM – 8 PM ET.

@Cytokinetics Was really excited about Aficamten approval however Optumrx is denying coverage and upholding appeal. What can one do when such a major insurer isnt working with you?

$CYTK: Today, we reported our fourth quarter 2025 financial results. Our senior management team will provide more details in a conference call at 4:30 p.m. ET. bit.ly/4ryyFp4

@JainySavlaMD @JainySavlaMD Please call 833-MYQORZO or (833-697-6796).

Hey @Cytokinetics - I tried writing for Aficamten today. Ran into a number of issues. Is there someone we can give feedback to that is higher level than our area rep? Would like to see the process work smoothly...

Our new medicine for the treatment of adults with symptomatic oHCM is now FDA-approved. This approval is the result of years of clinical research and collaboration with the HCM community, and most importantly, marks progress for patients. #HCM #CardioTwitter

$CYTK: We'll be presenting at the annual #JPM25 in San Francisco on January 12. We're looking forward to sharing what's next as we continue to advance our mission to meaningfully improve the lives of patients with diseases of impaired muscle function. bit.ly/49Ln5Q7

Today’s @US_FDA announcement is a significant milestone for Cytokinetics. Thank you to the patients, families, investigators, and advocates who helped make this moment possible. #TeamCyto #Biopharma

We’re excited to announce that the @US_FDA has approved our new medicine for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).  Learn more here: bit.ly/48MHEMF #HCM #CardioTwitter

$CYTK: We’re hosting an investor webcast today to discuss the @US_FDA approval of our new medicine. Tune in live here: bit.ly/4pSFocA #Biopharma

Today we announced an update from the EMA’s Committee for Medicinal Products for Human Use (CHMP) regarding our investigational cardiac myosin inhibitor. bit.ly/3MEeB5a #Biopharma #cardiotwitter

We’re at the AHA 2025 in New Orleans! Visit us at booth #3411. #AHA25 #HCM #HeartFailure #Cardiology #CardioTwitter

Be sure to join us for a learning studio on Saturday at #AHA25. Follow a patient living with oHCM, as she sits down with a cardiologist to share her path to diagnosis and the profound effects it has had on her life. bit.ly/3L4chnq #HCM #Cardiology #CardioTwitter

$CYTK: Today, we reported our third quarter 2025 financial results. Our senior management team will provide more details in a conference call at 4:30 p.m. ET. bit.ly/3JJszBI

If you'll be at HCMS 2025, be sure to join us for a satellite symposium exploring leading approaches for diagnosing and managing oHCM and the vital contributions different specialties bring to patient care. bit.ly/4qsbYTq #HCMS #HCM #Cardiology #CardioTwitter

We were proud to support and attend the first @HcmPatient Meeting in #Austria! The event brought together patients, healthcare providers and researchers to learn and connect in support of HCM advocacy. bit.ly/3JhAAxx #HCM #CardioTwitter #TeamCyto #HCMMeeting

We're looking forward to attending HCMS 2025 Scientific Sessions in New Orleans on November 7. We're excited to be joining HCM experts to explore innovative research. bit.ly/3KRSabY #HCMS #HCM #CardioTwitter #AHA2025

We're excited to attending the AHA 2025 in New Orleans, November 7–10, where we'll be connecting with global leaders to explore the future of cardiovascular health and science. bit.ly/48RLEfp #AHA2025 #HCM #HeartFailure #CardioTwitter

We’re at the HFSA Annual Scientific Meeting 2025 in Minneapolis! Come visit us at booth #707. #HFSA2025 #HeartFailure #HCM #CardioTwitter